Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Fineline Cube Aug 21, 2026
Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Fineline Cube Aug 21, 2026
Company Deals

Biocytogen Pharmaceuticals’ Eucure Biopharma Expands Partnership with Syncromune on Immunotherapies

Fineline Cube Aug 30, 2023

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd’s (HKG: 2315) wholly owned subsidiary, Eucure Biopharma, has announced...

Company Drug

CSPC Pharmaceutical’s Biosimilar Ozempic Equivalent Gets NMPA Clinical Trial Approval

Fineline Cube Aug 30, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its biosimilar version of Novo...

Company Drug

Jiangsu Yahong Meditech Gets NMPA Approval for APL1401 Ulcerative Colitis Trial

Fineline Cube Aug 30, 2023

Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer based in...

Company

Luye Pharma Group Reports H1 2023 Revenue Growth with Strong Oncology and CNS Sales

Fineline Cube Aug 30, 2023

China-based Luye Pharma Group (HKG: 2186) has announced its financial performance for the first half...

Company

Fosun Pharma Reports Moderate Revenue Growth and Increased R&D Spend in 2023 Interim Report

Fineline Cube Aug 30, 2023

Fosun Pharma (SHA: 600196) has released its 2023 interim financial report, recording revenues of RMB...

Company Drug

Roche’s Evrysdi Receives EC Approval for Expanded Indication in Infants with SMA

Fineline Cube Aug 30, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has received regulatory approval from the European Commission (EC)...

Company Drug

MSD’s Keytruda Gains EC Approval for First-Line HER2-Positive Gastric Cancer Treatment

Fineline Cube Aug 30, 2023

The European Commission (EC) has granted an additional indication to Merck, Sharp & Dohme (MSD;...

Company Drug

BMS’ Reblozyl Expands Indication to Include First-Line MDS-Related Anemia Treatment

Fineline Cube Aug 30, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has received an indication extension approval from the US Food...

Company Policy / Regulatory

HHS Releases List of 10 Drugs for Medicare Price Negotiations Starting 2026

Fineline Cube Aug 30, 2023

The Department of Health and Human Services (HHS) in the US has released a list...

Company Drug

ImmunoTech Biopharm’s EAL Earns Breakthrough Therapy Designation for HCC Recurrence Prevention

Fineline Cube Aug 29, 2023

The Center for Drug Evaluation (CDE) in China has indicated on its website that Immunotech...

Company Deals

Mabwell Bioscience Secures Deal with UNILAB for Biosimilar Humira in the Philippines

Fineline Cube Aug 29, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing and supply agreement...

Company Deals

HanchorBio and Henlius Pharmaceutical Enter Strategic Collaboration for Immunotherapies

Fineline Cube Aug 29, 2023

Taiwan-based HanchorBio has entered into a strategic cooperation framework agreement with Shanghai-headquartered Shanghai Henlius Biotech,...

Company Medical Device

Novocure’s TTFields Misses Overall Survival Endpoint in Ovarian Cancer Phase III Trial

Fineline Cube Aug 29, 2023

Switzerland-based Novocure (NASDAQ: NVCR) has experienced a setback with its Tumor Treating Fields (TTFields) product,...

Company Drug

Harbour BioMed’s HBM9033 ADC Receives US FDA IND Clearance for Clinical Trials

Fineline Cube Aug 29, 2023

China-based Harbour BioMed (HKG: 2142) has announced receiving Investigational New Drug (IND) clearance from the...

Company Deals

Sandoz Expands Anti-Infective Portfolio with Acquisition of Astellas Pharma’s Antifungal Mycamine

Fineline Cube Aug 29, 2023

Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz has bolstered its global anti-infectives portfolio with the acquisition...

Company Deals

BMS Partners with Cellares for Automated CAR-T Cell Therapy Production

Fineline Cube Aug 29, 2023

Pharmaceutical giant Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with cell therapy...

Company Deals

Takeda and BridGene Biosciences Achieve Milestone in Neurodegenerative Disorder Target Identification

Fineline Cube Aug 29, 2023

A 2021 collaboration between Japan’s Takeda (TYO: 4502) and US-based BridGene Biosciences has successfully reached...

Company

Lundbeck A/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales

Fineline Cube Aug 29, 2023

Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has released its financial report for the...

Company Drug

Janssen Submits Indication Extension Application for Balversa in Urothelial Carcinoma Treatment

Fineline Cube Aug 29, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has submitted an indication extension...

Company Drug

Zhejiang Huahai Pharmaceutical Receives FDA Approval for Generic Vyvanse

Fineline Cube Aug 29, 2023

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a China-based pharmaceutical company, has announced the receipt...

Posts pagination

1 … 526 527 528 … 711

Recent updates

  • METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines
  • CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors
  • LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval
  • China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect
  • Boehringer Ingelheim Upgrades China Strategy with New Shanghai R&D Center, Deepening Investment in Pharma and Animal Health
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Company Drug

CStone’s CS5007 IND Approved by NMPA, Advancing EGFR/HER3 Bispecific ADC for EGFR‑Resistant Tumors

Company Drug

LongBio Pharma’s LP‑003 BLA Accepted by NMPA for Seasonal Allergic Rhinitis, Advancing Novel Anti‑IgE Antibody Toward China Approval

Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.